Session

IBD (Posters)

IMPACT OF INFLAMMATORY BOWEL DISEASE ON THE QUALITY OF LIFE OF PATIENT’S HOUSEHOLD MEMBERS
IMPACT OF INFLAMMATORY BOWEL DISEASE ON THE QUALITY OF LIFE OF PATIENT’S HOUSEHOLD MEMBERS

IBD (Posters)  et al.

THERAPEUTIC DRUG MONITORING: STANDARDIZATION OF PROMONITOR QUICK IFX AND PROMONITOR QUICK ADL POINT OF CARE TESTS WITH WHO INTERNATIONAL STANDARDS FOR THE QUANTIFICATION OF INFLIXIMAB AND ADALIMUMAB IN WHOLE BLOOD AND SERUM
THERAPEUTIC DRUG MONITORING: STANDARDIZATION OF PROMONITOR QUICK IFX AND PROMONITOR QUICK ADL POINT OF CARE TESTS WITH WHO INTERNATIONAL STANDARDS FOR THE QUANTIFICATION OF INFLIXIMAB AND ADALIMUMAB IN WHOLE BLOOD AND SERUM

IBD (Posters)  et al.

IN HIGHLY REFRACTORY ULCERATIVE COLITIS PATIENTS, USTEKINUMAB IS A GOOD THERAPEUTIC OPTION
IN HIGHLY REFRACTORY ULCERATIVE COLITIS PATIENTS, USTEKINUMAB IS A GOOD THERAPEUTIC OPTION

IBD (Posters)  et al.

REAL-LIFE EXPERIENCE OF ANTI-DRUG ANTIBODIES AGAINST ANTI-TNF AGENTS AT TWO TERTIARY CARE PAEDIATRIC INFLAMMATORY BOWEL DISEASE CENTRES
REAL-LIFE EXPERIENCE OF ANTI-DRUG ANTIBODIES AGAINST ANTI-TNF AGENTS AT TWO TERTIARY CARE PAEDIATRIC INFLAMMATORY BOWEL DISEASE CENTRES

IBD (Posters)  et al.

CORRELATION OF THE PROMONITOR QUICK ADL LATERAL FLOW-BASED POINT OF CARE TEST TO QUANTIFY ADALIMUMAB IN A FINGER PRICK OR SERUM SAMPLES WITH THE REFERENCE ELISA TECHNIQUE
CORRELATION OF THE PROMONITOR QUICK ADL LATERAL FLOW-BASED POINT OF CARE TEST TO QUANTIFY ADALIMUMAB IN A FINGER PRICK OR SERUM SAMPLES WITH THE REFERENCE ELISA TECHNIQUE

IBD (Posters)  et al.

FACTORS ASSOCIATED WITH CUMULATIVE BOWEL DAMAGE USING LEMANN INDEX IN CROHN’S DISEASE – A TERTIATY CENTER EXPERIENCE
FACTORS ASSOCIATED WITH CUMULATIVE BOWEL DAMAGE USING LEMANN INDEX IN CROHN’S DISEASE – A TERTIATY CENTER EXPERIENCE

IBD (Posters)  et al.

BERBERINE SUPPLEMENTATION SIGNIFICANTLY IMPROVED ANTI-TNF-ALPHA EFFICACY IN MURINE COLITISMICEHUMANIZED WITH NON-RESPONDER GUT MICROBIOTA
BERBERINE SUPPLEMENTATION SIGNIFICANTLY IMPROVED ANTI-TNF-ALPHA EFFICACY IN MURINE COLITISMICEHUMANIZED WITH NON-RESPONDER GUT MICROBIOTA

IBD (Posters)  et al.

ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION
ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION

IBD (Posters)  et al.

THE INTERACTION BETWEENSEROTONIN REUPTAKE TRANSPORTERAND BRAIN-DERIVED NEUROTROPHIC FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS
THE INTERACTION BETWEENSEROTONIN REUPTAKE TRANSPORTERAND BRAIN-DERIVED NEUROTROPHIC FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS

IBD (Posters)  et al.

MAGNIFI-CD INDEX IS A STRONG PROGNOSTIC FACTOR IN PATIENTS WITH PERIANAL FISTULIZING CROHN’S DISEASE
MAGNIFI-CD INDEX IS A STRONG PROGNOSTIC FACTOR IN PATIENTS WITH PERIANAL FISTULIZING CROHN’S DISEASE

IBD (Posters)  et al.

IN PATIENTS WITH CROHN'S DISEASE, FECAL CALPROTECTIN DROP-SLOPE DURING INDUCTION WITH USTEKINUMAB CAN AFFECT ITS LEVELS AND DISCRIMINATE THE NEED FOR INTENSIFICATION AT WEEK 52
IN PATIENTS WITH CROHN'S DISEASE, FECAL CALPROTECTIN DROP-SLOPE DURING INDUCTION WITH USTEKINUMAB CAN AFFECT ITS LEVELS AND DISCRIMINATE THE NEED FOR INTENSIFICATION AT WEEK 52

IBD (Posters)  et al.

EFFICACY AND SAFETY OF MESENCHYMAL STEM CELL THERAPY WITH DARVADSTROCEL FOR COMPLEX PERIANAL FISTULIZING CROHN´S DISEASE: MULTICENTRIC EXPERIENCE IN THE BASQUE COUNTRY AND NAVARRE
EFFICACY AND SAFETY OF MESENCHYMAL STEM CELL THERAPY WITH DARVADSTROCEL FOR COMPLEX PERIANAL FISTULIZING CROHN´S DISEASE: MULTICENTRIC EXPERIENCE IN THE BASQUE COUNTRY AND NAVARRE

IBD (Posters)  et al.

PATIENTS PERSPECTIVE ON SWITCHING FROM INTRAVENOUS TO SUCUTANEOUS THERAPY
PATIENTS PERSPECTIVE ON SWITCHING FROM INTRAVENOUS TO SUCUTANEOUS THERAPY

IBD (Posters)  et al.

INTESTINAL CD8+ T CELL EXHAUSTION IS LINKED TO DISEASE ACTIVITY IN ULCERATIVE COLITIS
INTESTINAL CD8+ T CELL EXHAUSTION IS LINKED TO DISEASE ACTIVITY IN ULCERATIVE COLITIS

IBD (Posters)  et al.

THE IMPACT OF DRUG LEVELS TO ANTI-TNF AND ANTI-INTEGRIN AGENTS ON COVID-19 VACCINE RESPONSE IN PATIENTS WITH IBD
THE IMPACT OF DRUG LEVELS TO ANTI-TNF AND ANTI-INTEGRIN AGENTS ON COVID-19 VACCINE RESPONSE IN PATIENTS WITH IBD

IBD (Posters)  et al.

THE VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL FOR CROHN'S DISEASE EFFECTIVELY PREDICTS CLINICAL REMISSION AT 54 WEEKS IN A "REAL WORLD" SETTING
THE VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL FOR CROHN'S DISEASE EFFECTIVELY PREDICTS CLINICAL REMISSION AT 54 WEEKS IN A "REAL WORLD" SETTING

IBD (Posters)  et al.

MEDICAL TREATMENT OF VEO-IBD EXPOSES CHILDREN TO CRITICAL EXCIPIENTS – RESULTS FROM A RETROSPECTIVE OBSERVATIONAL SINGLE CENTER ANALYSIS
MEDICAL TREATMENT OF VEO-IBD EXPOSES CHILDREN TO CRITICAL EXCIPIENTS – RESULTS FROM A RETROSPECTIVE OBSERVATIONAL SINGLE CENTER ANALYSIS

IBD (Posters)  et al.

FOOD ADDITIVE NANOPARTICLES IS ASSOCIATED WITH SPECIFIC PRO-INFLAMMATORY BACTERIAL CHANGES IN CROHN’S DISEASE. THE ENIGMA STUDY
FOOD ADDITIVE NANOPARTICLES IS ASSOCIATED WITH SPECIFIC PRO-INFLAMMATORY BACTERIAL CHANGES IN CROHN’S DISEASE. THE ENIGMA STUDY

IBD (Posters)  et al.

THE ROLE OF THE GUT MICROBIOTA AND EXPRESSION OF TIGHT JUNCTION PROTEINS IN ALLEVIATION BY INTESTINAL ALKALINE PHOSPHATASE TREATMENT OF EXPERIMENTAL COLITIS EXACERBATED IN HIGH-FAT-DIET FED MICE BY FORCED PHYSICAL ACTIVITY
THE ROLE OF THE GUT MICROBIOTA AND EXPRESSION OF TIGHT JUNCTION PROTEINS IN ALLEVIATION BY INTESTINAL ALKALINE PHOSPHATASE TREATMENT OF EXPERIMENTAL COLITIS EXACERBATED IN HIGH-FAT-DIET FED MICE BY FORCED PHYSICAL ACTIVITY

IBD (Posters)  et al.

CROHN'S DISEASE EXCLUSION DIET (CDED) FOR THE TREATMENT OF CROHN'S DISEASE – AN OBSERVATIONAL STUDY FROM A TERTIARY CENTER
CROHN'S DISEASE EXCLUSION DIET (CDED) FOR THE TREATMENT OF CROHN'S DISEASE – AN OBSERVATIONAL STUDY FROM A TERTIARY CENTER

IBD (Posters)  et al.

Item 561 - 580 / 612
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
29
30 31